References
- Shultz DB, Filippi AR, Thariat J, Mornex F, Loo BW, Jr., Ricardi U. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol 2014; 9: 1426-33. doi:10.1097/JTO.0000000000000317
- Shah JL, Loo BW, Jr. Stereotactic ablative radiotherapy for early-stage lung cancer. Semin Radiat Oncol 2017; 27: 218-28. doi: 10.1016/j.semradonc.2017.03.001
- Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70: 685-92. doi: 10.1016/j.ijrobp.2007.10.053
- Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-6. doi: 10.1001/jama.2010.261
- Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101: 1623-31. doi: 10.1002/cncr.20539
- Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24: 4833-9. doi: 10.1200/JCO.2006.07.5937
- Tekatli H, Haasbeek N, Dahele M, De Haan, Verbakel PW, Bongers E, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-small cell lung cancer. J Thorac Oncol 2016; 11: 1081-9. doi: 10.1016/j.jtho.2016.03.008
- Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 2016; 6: e27-33. doi: 10.1016/j.prro.2015.09.012
- Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryanet WF, al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol 2019; 37: 1316-25. doi: 10.1200/JCO.18.00622
- Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 2015; 89: 50-6. doi: 10.1016/j.lungcan.2015.04.014
- Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys 2014; 88: 1120-8. doi: 10.1016/j.ijrobp.2014.01.022
- Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011; 6: 2036-43. 12. doi: 10.1097/JTO.0b013e31822e71d8
- Raman S, Yau V, Pineda S, Le LW, Lau A, Bezjak A, et al. Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience. Clin Lung Cancer 2018; 19: e803-e810. doi: 10.1016/j.cllc.2018.06.001
- Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88: 20150036. doi: 10.1259/bjr.20150036
- Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glicket D, et al. SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer - a safety and efficacy trial. Clin Lung Cancer 2018; 19: e529-32. doi: 10.1016/j.cllc.2018.04.001
- Matsuo Y. A systematic literature review on salvage radiotherapy for local or regional recurrence after previous stereotactic body radiotherapy for lung cancer. Technol Cancer Res Treat 2018; 17: 1533033818798633. doi: 10.1177/1533033818798633
- Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, et al. Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 2011; 101: 260-6. doi: 10.1016/j.radonc.2011.09.012
- Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, et al. Long-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non-small cell lung cancer: a phase II clinical trial. J Thorac Oncol 2017; 12: 983-92. doi: 10.1016/j.jtho.2017.02.018
- Binkley MS, Hiniker SM, Chaudhuri A, Maxim PG, Diehn M, Loo BW Jr, et al. Dosimetric factors and toxicity in highly conformal thoracic reirradiation. Int J Radiat Oncol Biol Phys 2016; 94: 808-15. doi: 10.1016/j.ijrobp.2015.12.007
- Shultz DB, Trakul N, Maxim PG, Diehn M, Loo BW, Jr. Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. Pract Radiat Oncol 2014; 4: 272-8. doi: 10.1016/j.prro.2013.08.005